DE602006020611D1 - Krebsbehandlungsverfahren - Google Patents

Krebsbehandlungsverfahren

Info

Publication number
DE602006020611D1
DE602006020611D1 DE602006020611T DE602006020611T DE602006020611D1 DE 602006020611 D1 DE602006020611 D1 DE 602006020611D1 DE 602006020611 T DE602006020611 T DE 602006020611T DE 602006020611 T DE602006020611 T DE 602006020611T DE 602006020611 D1 DE602006020611 D1 DE 602006020611D1
Authority
DE
Germany
Prior art keywords
treatment method
cancer treatment
cancer
administration
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006020611T
Other languages
English (en)
Inventor
Arundathy Nirmalini Pandite
Bonnie F Whitehead
Peter T C Ho
Albert Benjamin Suttle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of DE602006020611D1 publication Critical patent/DE602006020611D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE602006020611T 2005-11-29 2006-11-29 Krebsbehandlungsverfahren Active DE602006020611D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74030805P 2005-11-29 2005-11-29
PCT/US2006/045777 WO2007064753A2 (en) 2005-11-29 2006-11-29 Cancer treatment method

Publications (1)

Publication Number Publication Date
DE602006020611D1 true DE602006020611D1 (de) 2011-04-21

Family

ID=37847172

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006020611T Active DE602006020611D1 (de) 2005-11-29 2006-11-29 Krebsbehandlungsverfahren

Country Status (12)

Country Link
US (1) US20090005406A1 (de)
EP (2) EP1954281B1 (de)
JP (1) JP2009517397A (de)
AT (1) ATE500831T1 (de)
CY (1) CY1111390T1 (de)
DE (1) DE602006020611D1 (de)
DK (1) DK1954281T3 (de)
ES (1) ES2359517T3 (de)
HR (1) HRP20110244T1 (de)
PL (1) PL1954281T3 (de)
SI (1) SI1954281T1 (de)
WO (1) WO2007064753A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058307A1 (de) 2007-11-12 2009-05-13 Cellzome Ag Verfahren zur Identifizierung von mit JAK-Kinase wechselwirkenden Molekülen und zur JAK-Kinase-Reinigung
JP2013508396A (ja) * 2009-10-23 2013-03-07 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 組成物および方法
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
CA2814439A1 (en) 2010-10-27 2012-05-03 Novartis Ag Dosing regimes for the treatment of ocular vascular disease
JP6200893B2 (ja) * 2011-10-31 2017-09-20 ノバルティス アーゲー パゾパニブ製剤
MX2014009892A (es) * 2012-02-17 2015-02-12 Pharmacyclics Inc Combinaciones de inhibidor de histona desacetilasa y pazopanib y usos de las mismas.
CN103319410B (zh) * 2012-03-22 2016-04-06 天津药物研究院 一种吲唑化合物的合成方法
CN103232443B (zh) * 2013-02-01 2014-12-10 天津药物研究院 一种吲唑衍生物的晶型及其制备和用途
US10730859B2 (en) * 2013-11-05 2020-08-04 Laurus Labs Limited Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CN110878089A (zh) * 2018-09-05 2020-03-13 江苏豪森药业集团有限公司 一种盐酸帕唑帕尼的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156306A0 (en) 2000-12-21 2004-01-04 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
AU2002236765A1 (en) 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AU2003276125B2 (en) 2002-06-17 2007-05-17 Smithkline Beecham Corporation Chemical process
JP2007532658A (ja) * 2004-04-16 2007-11-15 スミスクライン ビーチャム コーポレーション がんの治療方法

Also Published As

Publication number Publication date
EP1954281A2 (de) 2008-08-13
HRP20110244T1 (hr) 2011-04-30
SI1954281T1 (sl) 2011-06-30
US20090005406A1 (en) 2009-01-01
WO2007064753A2 (en) 2007-06-07
WO2007064753A3 (en) 2007-11-29
DK1954281T3 (da) 2011-05-16
ES2359517T3 (es) 2011-05-24
JP2009517397A (ja) 2009-04-30
ATE500831T1 (de) 2011-03-15
PL1954281T3 (pl) 2011-07-29
EP2380572A1 (de) 2011-10-26
EP1954281B1 (de) 2011-03-09
CY1111390T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
DE602006020611D1 (de) Krebsbehandlungsverfahren
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
DK1968594T3 (da) Behandling af okulære neovaskulære lidelser, såsom makulær degeneration, striae angioides og makulært ødem
NO2010020I1 (no) 5-{{4-[(2,3-dimetyl-2H-indazot-6-yl)(metyl)amino]pyrimidin-2-yl}amino)-2-metylbenzensulfonamid Pazopanib.
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
EA200501333A1 (ru) 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DK1782825T3 (da) Behandling af glycogenlagringssygdom type II
WO2007143483A3 (en) Combination of pazopanib and lapatinib for treating cancer
DK1926729T3 (da) Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
EA200900034A1 (ru) Применение ингибитора р38 киназы для лечения психиатрических расстройств
EA200702027A1 (ru) Дерматологические композиции и соли для лечения дерматологических заболеваний
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
DK1684763T3 (da) 6-Aryl-7-halogen-imidazo(1,2-a)pyrimidiner som anticancermiddel
ITRM20030442A1 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.
DE60214558D1 (de) 2-(AMINOMETHYL)TETRAHYDRO-9-OXA-1,3-DIAZACYCLOPENTAcAÜNAPHTHALINYLDERIVATE MIT ANTIPSYCHOTISCHER WIRKUNG